AAPL   381.09 (-0.43%)
MSFT   212.26 (-0.96%)
FB   240.97 (-1.44%)
GOOGL   1,514.18 (-0.29%)
AMZN   3,180.31 (-0.07%)
CGC   16.59 (+3.56%)
MU   50.16 (+0.36%)
GE   6.68 (+1.52%)
TSLA   1,417.81 (+1.69%)
T   29.80 (+0.88%)
ACB   11.91 (+1.19%)
F   5.97 (+2.05%)
GILD   76.45 (+2.33%)
BAC   23.23 (+2.02%)
BA   175.52 (+1.29%)
AAPL   381.09 (-0.43%)
MSFT   212.26 (-0.96%)
FB   240.97 (-1.44%)
GOOGL   1,514.18 (-0.29%)
AMZN   3,180.31 (-0.07%)
CGC   16.59 (+3.56%)
MU   50.16 (+0.36%)
GE   6.68 (+1.52%)
TSLA   1,417.81 (+1.69%)
T   29.80 (+0.88%)
ACB   11.91 (+1.19%)
F   5.97 (+2.05%)
GILD   76.45 (+2.33%)
BAC   23.23 (+2.02%)
BA   175.52 (+1.29%)
AAPL   381.09 (-0.43%)
MSFT   212.26 (-0.96%)
FB   240.97 (-1.44%)
GOOGL   1,514.18 (-0.29%)
AMZN   3,180.31 (-0.07%)
CGC   16.59 (+3.56%)
MU   50.16 (+0.36%)
GE   6.68 (+1.52%)
TSLA   1,417.81 (+1.69%)
T   29.80 (+0.88%)
ACB   11.91 (+1.19%)
F   5.97 (+2.05%)
GILD   76.45 (+2.33%)
BAC   23.23 (+2.02%)
BA   175.52 (+1.29%)
AAPL   381.09 (-0.43%)
MSFT   212.26 (-0.96%)
FB   240.97 (-1.44%)
GOOGL   1,514.18 (-0.29%)
AMZN   3,180.31 (-0.07%)
CGC   16.59 (+3.56%)
MU   50.16 (+0.36%)
GE   6.68 (+1.52%)
TSLA   1,417.81 (+1.69%)
T   29.80 (+0.88%)
ACB   11.91 (+1.19%)
F   5.97 (+2.05%)
GILD   76.45 (+2.33%)
BAC   23.23 (+2.02%)
BA   175.52 (+1.29%)
Log in

NASDAQ:ELGXEndologix Stock Price, Forecast & News

$0.26
-0.05 (-15.90 %)
(As of 07/10/2020 11:04 AM ET)
Add
Compare
Today's Range
$0.25
Now: $0.26
$0.30
50-Day Range
$0.31
MA: $0.84
$1.22
52-Week Range
$0.23
Now: $0.26
$7.20
Volume4.00 million shs
Average Volume3.77 million shs
Market Capitalization$5.07 million
P/E RatioN/A
Dividend YieldN/A
Beta0.73
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Read More
Endologix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$143.37 million
Book Value$3.56 per share

Profitability

Net Income$-64,760,000.00

Miscellaneous

Employees528
Market Cap$5.07 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.

Endologix (NASDAQ:ELGX) Frequently Asked Questions

How has Endologix's stock been impacted by COVID-19 (Coronavirus)?

Endologix's stock was trading at $0.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ELGX stock has decreased by 70.2% and is now trading at $0.28. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Endologix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Endologix.

When is Endologix's next earnings date?

Endologix is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Endologix.

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) issued its quarterly earnings results on Monday, May, 11th. The medical instruments supplier reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by $0.13. The medical instruments supplier earned $28.51 million during the quarter, compared to analysts' expectations of $28.50 million. Endologix had a negative return on equity of 63.96% and a negative net margin of 44.65%. View Endologix's earnings history.

When did Endologix's stock split? How did Endologix's stock split work?

Endologix shares reverse split on the morning of Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ELGX?

3 brokers have issued 1 year price targets for Endologix's shares. Their forecasts range from $1.00 to $7.00. On average, they anticipate Endologix's share price to reach $4.00 in the next year. This suggests a possible upside of 1,328.6% from the stock's current price. View analysts' price targets for Endologix.

Has Endologix been receiving favorable news coverage?

Headlines about ELGX stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Endologix earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Endologix.

Are investors shorting Endologix?

Endologix saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 236,500 shares, a decrease of 37.6% from the June 15th total of 379,300 shares. Based on an average daily volume of 338,100 shares, the days-to-cover ratio is currently 0.7 days. Currently, 1.4% of the company's shares are short sold. View Endologix's Current Options Chain.

Who are some of Endologix's key competitors?

What other stocks do shareholders of Endologix own?

Who are Endologix's key executives?

Endologix's management team includes the following people:
  • Mr. John Onopchenko, CEO & Director (Age 60)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)
  • Mr. Jeffrey S. Brown, Chief Operations Officer
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 49)

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $0.28.

How big of a company is Endologix?

Endologix has a market capitalization of $5.37 million and generates $143.37 million in revenue each year. The medical instruments supplier earns $-64,760,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Endologix employs 528 workers across the globe.

What is Endologix's official website?

The official website for Endologix is www.endologix.com.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.